---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-056227"
form_type: "8-K"
ticker: "IXHL"
cik: "0001873875"
company_name: "Incannex Healthcare Inc."
filed_at: "2026-05-14T11:30:31+00:00"
generated_at: "2026-05-14T11:37:10.397549+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Incannex commences DReAMzz study of IHL-42X for obstructive sleep apnea

## Summary
- All 14 clinical trial sites identified; site contracting underway; import/export permits secured.
- Study is a crossover dose optimization to de-risk Phase III pathway for IHL-42X.
- Previously reported Phase II RePOSA showed statistically significant AHI reductions and improved oxygenation.
- FDA granted Fast Track designation for IHL-42X in OSA.
- Manufacturing of clinical trial supply completed; global distribution partner onboarded.

## SEC filing metadata
- accession: 0001213900-26-056227
- form_type: 8-K
- ticker: IXHL
- cik: 0001873875
- company_name: Incannex Healthcare Inc.
- filed_at: 2026-05-14T11:30:31+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1873875/000121390026056227/0001213900-26-056227-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1873875/000121390026056227/ea0290292-8k_incannex.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-056227
- JSON: https://secwatch.observer/filing/0001213900-26-056227.json
- Plain text: https://secwatch.observer/filing/0001213900-26-056227.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.